Literature DB >> 10611439

Effect of non-peptide tachykinin NK(1) receptor antagonists on non-adrenergic, non-cholinergic neurogenic mucus secretion in ferret trachea.

A M Khawaja1, Y Liu, D F Rogers.   

Abstract

We investigated, in ferret trachea in vitro, the binding characteristics and the inhibition of non-adrenergic, non-cholinergic (NANC) neural mucus secretion of four tachykinin receptor antagonists: the non-peptide tachykinin NK(1) receptor antagonists CGP 49823 ((2R,4S)-2-benzyl-1-(3, 5-dimethylbenzoyl)-4-(quinolin-micro-ylmethyl amino) piperidine), CGP 55000 ((2R,4S)-2-benzyl-1-(3, 5-bistrifluoromethyl-benzoyl)-4-(quinolinyl-methylamino)piperidine ) and CP 99,994 ((+)-(2S,3S)-3-methoxybenzyl amino)-2-phenylpiperidine), and the peptide tachykinin NK(2) receptor antagonist MEN 10,627 (cyclo(Met-Asp-Trp-Phe-Dap-Leu)cyclo(2beta-5beta)). CGP 49823, CGP 55000 and CP 99,994 concentration-dependently displaced [125I]Bolton-Hunter substance P binding in tracheal membranes with Hill coefficients not different from unity and IC(50) values of 1.4, 1.7 and 1.3 nM, respectively. In contrast, MEN 10,627 displaced binding according to a two-site model, with IC(50)s of 0.2 nM and 1. 3 microM. Electrical stimulation of tracheal segments with adrenoceptor and cholinoceptor blockade increased output of the mucus marker 35SO(4) by 59% above baseline (representing the NANC neural secretory response). CGP 49823, CGP 55000 or CP 99,994 concentration-dependently inhibited NANC neural secretion with IC(50) values of 30, 8 and 120 nM, respectively. In contrast, MEN 10, 627 (3 microM) did not inhibit secretion. The NK(1) antagonists, but not the NK(2) antagonist, inhibited [Sar(9)]substance P-induced secretion, while none of the antagonists affected acetylcholine-induced secretion. We conclude that NANC neural secretion in ferret trachea in vitro is a useful test system for tachykinin NK(1) receptor antagonists with therapeutic potential in conditions of the airways in which tachykininergic mechanisms and mucus hypersecretion are implicated in pathophysiology, for example asthma and chronic bronchitis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10611439     DOI: 10.1016/s0014-2999(99)00694-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  Effect of the long-acting tachykinin NK(1) receptor antagonist MEN 11467 on tracheal mucus secretion in allergic ferrets.

Authors:  S Khan; Y C Liu; A M Khawaja; S Manzini; D F Rogers
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 2.  Liquid secretion properties of airway submucosal glands.

Authors:  Stephen T Ballard; Sarah K Inglis
Journal:  J Physiol       Date:  2003-12-05       Impact factor: 5.182

3.  Tachykinin NK3 and NK1 receptor activation elicits secretion from porcine airway submucosal glands.

Authors:  Jonathan E Phillips; John A Hey; Michel R Corboz
Journal:  Br J Pharmacol       Date:  2003-01       Impact factor: 8.739

Review 4.  Tachykinin receptors antagonism for asthma: a systematic review.

Authors:  Renata Ramalho; Raquel Soares; Nuno Couto; André Moreira
Journal:  BMC Pulm Med       Date:  2011-08-02       Impact factor: 3.317

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.